Cel Sci Corp Stock Net Asset
| CVM Stock | USD 0.61 0.01 1.61% |
CEL SCI Corp fundamentals help investors to digest information that contributes to CEL SCI's financial success or failures. It also enables traders to predict the movement of CEL Stock. The fundamental analysis module provides a way to measure CEL SCI's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CEL SCI stock.
CEL | Net Asset |
CEL SCI Corp Company Net Asset Analysis
CEL SCI's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current CEL SCI Net Asset | 30.53 M |
Most of CEL SCI's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CEL SCI Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CEL Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for CEL SCI is extremely important. It helps to project a fair market value of CEL Stock properly, considering its historical fundamentals such as Net Asset. Since CEL SCI's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CEL SCI's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CEL SCI's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
CEL Total Assets
Total Assets |
|
Based on the recorded statements, CEL SCI Corp has a Net Asset of 30.53 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
CEL Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CEL SCI's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CEL SCI could also be used in its relative valuation, which is a method of valuing CEL SCI by comparing valuation metrics of similar companies.CEL SCI is currently under evaluation in net asset category among its peers.
CEL SCI Current Valuation Drivers
We derive many important indicators used in calculating different scores of CEL SCI from analyzing CEL SCI's financial statements. These drivers represent accounts that assess CEL SCI's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CEL SCI's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 468.7M | 446.9M | 133.3M | 55.6M | 50.0M | 83.9M | |
| Enterprise Value | 467.1M | 426.8M | 126.0M | 65.0M | 58.5M | 82.9M |
CEL Fundamentals
| Return On Equity | -2.5 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | 50.73 M | ||||
| Shares Outstanding | 63.81 M | ||||
| Shares Owned By Insiders | 2.91 % | ||||
| Shares Owned By Institutions | 10.46 % | ||||
| Number Of Shares Shorted | 4.43 M | ||||
| Price To Earning | (1.14) X | ||||
| Price To Book | 4.64 X | ||||
| Price To Sales | 11,797 X | ||||
| Gross Profit | (25.36 M) | ||||
| EBITDA | (27.56 M) | ||||
| Net Income | (32.19 M) | ||||
| Cash And Equivalents | 22.67 M | ||||
| Cash Per Share | 0.65 X | ||||
| Total Debt | 13.57 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 7.71 X | ||||
| Book Value Per Share | 0.16 X | ||||
| Cash Flow From Operations | (22.85 M) | ||||
| Short Ratio | 18.05 X | ||||
| Earnings Per Share | (0.52) X | ||||
| Target Price | 7.73 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 44.71 M | ||||
| Total Asset | 30.53 M | ||||
| Retained Earnings | (487.09 M) | ||||
| Working Capital | 1.33 M | ||||
| Current Asset | 5.89 M | ||||
| Current Liabilities | 4.01 M | ||||
| Net Asset | 30.53 M |
About CEL SCI Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CEL SCI Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CEL SCI using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CEL SCI Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out CEL SCI Piotroski F Score and CEL SCI Altman Z Score analysis. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.